GlaxoSmithKline Pharmaceuticals Limited at its board meeting held on January 7, 2021 approved the Cessation of Mr. Raju Krishnaswamy as a Director of the Company with effect from 27 January 2021 and to approved the appointment of Mr. Mark Dawson as a Non - Executive Director of the Company effective 28 January, 2021. Mark Dawson is Vice President of Manufacturing and Supply Chain for Primary and Established Products (PEP) within GSK's Pharmaceutical Business. Mark is accountable for the supply chain that manufactures all GSK Primary (API) products, Antibiotics supply chain and Regional Pharmaceutical manufacturing with 18 facilities located across Europe, Latam, MEA, India, China, Singapore and Australia. Additionally, he has accountability for all supply chain plann ing, logistics and warehousing operations into 105 global markets from Latam, Middle East, Africa, Russia/CIS, India, Pakistan, China and S Asia.